EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022

News provided by

Jan 22, 2014, 12:45 ET

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022

Summary

Autism Spectrum Disorders (ASD) is a group of incurable, developmental disabilities which affect the brain and are usually diagnosed between the ages of 18–24 months. ASD encompasses a broad spectrum of disorders in which the severity of the condition, the nature of impairment, the social and communication skills, time of onset of the condition, and the way the brain perceives information, vary among the affected individuals. Epidemiological literature suggests an increase in the diagnosed prevalence of ASD over time. However, it remains unclear whether the increase in the diagnosed prevalence is due to a true increase in the prevalence of ASD, or due to an increase in the diagnosis of ASD because of an increased availability and utilization of health services.

In 2012, there were 1,826,542 diagnosed prevalent cases of ASD in the 6MM, with approximately 90% of the diagnosed prevalent cases (1,630,499 prevalent cases) in the US alone. GlobalData epidemiologists forecast that there will be 1,952,647 diagnosed prevalent cases of ASD in the 6MM by 2022, with an overall annual growth rate (AGR) of 0.69% during the forecast period.

Better surveillance techniques and the creation of centralized ASD registries in all countries could provide robust and reliable data for determining the true burden of the condition. Evidence generated through additional research could be further utilized to formulate policies to control for the risk factors associated with ASD, and possibly reduce the incidence of ASD in the future.

Scope

- The Autism Spectrum Disorders EpiCast Report provides an overview of the risk factors and global trends of autism spectrum disorders in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast (2012–2022) of the prevalent cases of autism spectrum disorders segmented by age (in five-year increments beginning at age 0 and ending at age 19 years) and sex in the 6MM.
- The autism spectrum disorders epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global autism spectrum disorders market.
- Quantify patient populations in the global autism spectrum disorders market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for autism spectrum disorders therapeutics in each of the markets covered.
- Identify the percentage of prevalent cases with different subtypes of autism spectrum disorders.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 10
3.2.1 Intake of certain drugs during pregnancy increases the risk of ASD in children 11
3.2.2 Gestational complications elevates the risk of ASD 13
3.2.3 Familial history of psychiatric disorders in first-degree relatives is a strong predictor of ASD 14
3.2.4 Increasing maternal age raises the risk of ASD compared with increasing paternal age 16
3.2.5 Boys are more likely to develop ASD than girls 18
3.2.6 Neuropsychiatric disorders are highly prevalent in autistic patients 19
3.3 Global Trends 21
3.3.1 US 21
3.3.2 5EU 23
3.4 Forecast Methodology 24
3.4.1 Sources Used 25
3.4.2 Sources Not Used 26
3.4.3 Forecast Assumptions and Methods, Prevalent Cases 28
3.5 Epidemiology Forecast of ASD (2012–2022) 30
3.5.1 Diagnosed Prevalent Cases of ASD 30
3.5.2 Age-Specific Prevalent Cases of Diagnosed ASD 32
3.5.3 Sex-Specific Prevalent Cases of Diagnosed ASD 34
3.5.4 Age-Standardized Prevalence (%) of Diagnosed ASD 35
3.5.5 Prevalent Cases of Diagnosed ASD, by Subtype 36
3.6 Discussion 38
3.6.1 Epidemiological Forecast Insight 38
3.6.2 Limitations of the Analysis 40
3.6.3 Strengths of the Analysis 41
4 Appendix 42
4.1 Bibliography 42
4.2 About the Authors 46
4.2.1 Epidemiologists 46
4.2.2 Reviewers 46
4.2.3 Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy 47
4.2.4 Bonnie Bain, PhD, Global Head of Healthcare 48
4.3 About GlobalData 48
4.4 About EpiCast 49
4.5 Disclaimer 49

List of Tables

Table 1: Comparison Between DSM-IV and ICD-10 for Different Disorders of ASD 9
Table 2: Risk Factors and Comorbidities Associated with ASD 10
Table 3: Sources of Diagnosed Prevalence Data Used in the Analysis for ASD and its Subtypes 24
Table 4: 6MM, Prevalent Cases of Diagnosed ASD, Ages 0–19 Years, Boys and Girls, N, 2012–2022 31
Table 5: 6MM, Prevalent Cases of Diagnosed ASD, by Age, Boys and Girls, N (Row %), 2012 33
Table 6: 6MM, Prevalent Cases of Diagnosed ASD, by Sex, Ages 0–19 Years, N, Row (%), 2012 34
Table 7: 6MM, Prevalent Cases in the Different Subtypes of ASD, Ages 0–19 Years, Boys and Girls, N, Row (%), 2012 37

List of Figures

Figure 1: Total Prevalence of ASD, Age 8 Years, Boys and Girls, 2000–2008 22
Figure 2: 6MM, Prevalent Cases of Diagnosed ASD, Ages 0–19 Years, Boys and Girls, N, 2012–2022 31
Figure 3: 6MM, Prevalent Cases of Diagnosed ASD, by Age, Boys and Girls, N, 2012 33
Figure 4: 6MM, Prevalent Cases of Diagnosed ASD, by Sex, Ages 0–19 Years, N, 2012 35
Figure 5: 6MM, Age-Standardized Prevalence (%) of Diagnosed ASD, Ages 0–19 Years, Boys and Girls, 2012 36
Figure 6: 5EU, Prevalent Cases in the Different Subtypes of ASD, Ages 0–19 Years, Boys and Girls, N, 2012 38

Read the full report:
EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022
http://www.reportbuyer.com/pharma_healthcare/diseases/epicast_report_autism_spectrum_disorders_epidemiology_forecast_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer